If you have been trying to lose weight for some time, you may be wondering whether you need to manage it through diet and exercise alone, or whether medication or another form of treatment could help.
There is no single weight loss treatment that suits everyone. The right approach depends on your BMI, waist measurement, medical history, current medicines, previous attempts at weight management and, importantly, what you are realistically able to maintain over the longer term.
As a pharmacist and independent prescriber, I see weight management as a clinical issue rather than a question of willpower. Appetite, hormones, sleep, medication, mental health, genetics, activity levels and the food environment can all influence body weight. For some people, lifestyle changes are enough. For others, medication or specialist treatment is appropriate.
This guide explains the main weight loss treatment options available in the UK and how NHS and private treatment differ.
What counts as a weight loss treatment?
Weight management treatment can include:
- dietary and lifestyle changes
- structured behavioural support
- prescription medicines
- specialist weight management services
- bariatric surgery for people who meet the relevant criteria.
These approaches are not necessarily alternatives. In many cases, the most effective treatment combines more than one.
NICE recommends that weight management programmes for adults address diet, physical activity and behaviour change, with goals and support tailored to the individual. [1]
Before treatment is recommended, a healthcare professional should also consider your overall health rather than looking at weight in isolation. BMI is useful, but it does not tell us everything about health risk. For people with a BMI below 35 kg/m², NICE also recommends considering waist-to-height ratio as a practical measure of central adiposity. [2]
1. Lifestyle and behavioural treatment
Lifestyle treatment remains an important part of weight management, whether or not medication is prescribed.
That does not necessarily mean following a strict diet or spending hours in the gym. A clinically sensible approach usually looks at your overall energy intake, food quality, eating patterns, physical activity, sleep and the circumstances that make weight management difficult.
For example, useful changes might include:
- reducing portion sizes where appropriate
- increasing protein and fibre-rich foods
- reducing frequent high-calorie snacks and drinks
- planning meals rather than relying on convenience foods
- increasing walking or other forms of regular activity
- reducing prolonged periods of sitting
- identifying situations where eating is driven by habit, stress or boredom
- monitoring weight and other relevant measures over time.
NICE recommends an individualised dietary approach that creates an energy deficit while maintaining nutritional balance. It also recommends building towards appropriate levels of physical activity and providing support to help people maintain changes in the long term. [1]
This is important because weight regain is common. A short period of restrictive dieting may produce a quick change on the scales, but it does not necessarily provide a strategy for maintaining that change.
Very-low-calorie diets are also not a routine long-term solution. NICE recommends that diets providing fewer than 800 calories a day should only be considered in specialist services for people with obesity who have a clinically assessed need to lose weight rapidly, such as before surgery. [1]
For many people, a more moderate approach that can actually be maintained is preferable.
2. Prescription weight loss medicines
For some people, lifestyle measures alone do not produce enough weight loss, particularly where obesity is affecting health or appetite remains difficult to manage.
Prescription medicines can form part of a broader weight management plan. Current UK options include medicines such as tirzepatide, semaglutide, liraglutide and orlistat, although the precise licensing, eligibility criteria and NHS availability differ between medicines. [3]
You can read more about [internal link: weight loss treatment] and how prescription treatment may fit into an individual weight management plan.
GLP-1 and GLP-1/GIP medicines
The medicines receiving the most attention currently are the injectable treatments that act on gut hormones involved in appetite and satiety.
Semaglutide (Wegovy) is a GLP-1 receptor agonist. It helps reduce appetite and can make you feel fuller for longer. It is administered once weekly. Semaglutide is also available under other brand names for different indications, so it is important to use the product specifically licensed and prescribed for weight management rather than assuming that all semaglutide products are interchangeable. [3,4]
Tirzepatide (Mounjaro) acts on both GLP-1 and GIP receptors. It is also given once weekly and reduces appetite while increasing feelings of fullness. NICE recommends tirzepatide as an option for weight management in eligible adults, alongside a reduced-calorie diet and increased physical activity. [5]
The results seen in clinical trials can be substantial. In the SURMOUNT-1 trial, adults with obesity or overweight and weight-related health problems who received tirzepatide alongside lifestyle intervention had average weight reductions of approximately 15% to 21% after 72 weeks, depending on the dose. [6]
That does not mean everyone will lose the same amount of weight. Clinical trials provide useful evidence about what a treatment can achieve in a population, but individual results vary.
What about liraglutide?
Liraglutide (Saxenda) is another GLP-1 receptor agonist used for weight management in the UK. Unlike semaglutide and tirzepatide, it is administered daily rather than weekly.
NICE recommends liraglutide for certain adults with obesity as part of a specialist weight management service, alongside a reduced-calorie diet and increased physical activity. [7]
Availability and prescribing pathways can change, so anyone considering treatment should have their current options assessed rather than relying on an older list of medicines.
Orlistat
Orlistat works differently. Rather than affecting appetite hormones, it reduces the amount of dietary fat absorbed from the digestive system.
Because of the way it works, gastrointestinal side effects can occur, particularly if meals contain a high amount of fat. A healthcare professional should explain how to take it and what dietary changes are needed.
Orlistat remains one of the established medical options for weight management, although newer appetite-regulating medicines have changed the range of treatments available. [3]
Are weight loss injections safe?
Prescription weight loss medicines are not suitable for everyone, and “weight loss injection” does not mean risk-free.
With GLP-1 and GLP-1/GIP medicines, common side effects include nausea, vomiting and diarrhoea. These effects are often more noticeable when treatment is started or the dose is increased.
More serious adverse effects are uncommon, but they do occur. The MHRA has strengthened warnings concerning acute pancreatitis, including rare reports of severe, necrotising and fatal pancreatitis with GLP-1 and GLP-1/GIP medicines. [8]
There are also specific considerations around pregnancy, contraception, other medicines, surgery and certain medical conditions.
This is one reason I would always recommend a proper clinical assessment before starting treatment. Buying an injection online simply because it is advertised as a weight loss product is not an appropriate substitute for prescribing and monitoring.
The MHRA has also warned the public about obtaining GLP-1 medicines from illegal or unregulated sources. [3]
How do NHS weight loss treatments work?
NHS access depends on where you live, your clinical circumstances and the particular treatment.
In England, NHS prescribing of weight management medicines is subject to NICE recommendations and NHS England commissioning arrangements. Access is therefore not necessarily the same as obtaining a private prescription.
For example, NHS England is introducing tirzepatide into primary care through a phased approach. Under the current arrangements, initial access is focused on people with higher clinical need. One primary-care eligibility route includes a BMI of 35 kg/m² or above, adjusted where appropriate for ethnicity, together with four specified weight-related health conditions. [9]
Tirzepatide is also available through NHS specialist weight management services for people who meet the relevant NICE criteria. [9]
This phased approach means that someone may meet the medical criteria described in NICE guidance but still find that NHS access depends on the local service and commissioning pathway.
If you are considering NHS treatment, your GP practice, local integrated care board or specialist weight management service can explain what is currently available in your area.
What about private weight loss treatment?
Private treatment can provide another route for people who are clinically suitable for prescription medication but do not have access to NHS treatment, or who prefer a private service.
However, private does not mean that prescribing criteria should be ignored.
A responsible private service should still assess your BMI and health history, check for contraindications and interactions, discuss expected benefits and side effects, prescribe within the medicine’s UK licence, and provide appropriate follow-up.
For injectable medicines, dose increases are normally gradual. This allows the body time to adjust and gives the prescriber an opportunity to assess side effects, response and whether continuing treatment is appropriate.
Cost is also an important practical consideration. Private treatment generally involves paying for the clinical service and medicine yourself, and prices can vary considerably between providers, treatment doses and prescription arrangements. It is worth checking exactly what is included before starting: consultation fees, prescription charges, medication, follow-up appointments and ongoing clinical support may be priced separately.
Weight loss treatment is not simply about the number on the scales
When I assess someone for weight management treatment, I am interested in more than how many kilograms they want to lose.
We should consider whether excess weight is contributing to problems such as high blood pressure, type 2 diabetes, sleep apnoea, cardiovascular disease or reduced mobility. We should also consider current medicines, eating patterns, previous treatment attempts and whether there are symptoms or circumstances that need addressing first.
The aim may be weight loss, but the clinical goal is often broader: improving health, reducing disease risk, improving mobility, controlling blood glucose or blood pressure, and helping someone maintain those improvements.
This is also why treatment needs reviewing over time. A medicine that works well initially may need its dose adjusted, continued, changed or stopped depending on response and tolerability.
What about weight loss surgery?
For people with more severe obesity, bariatric surgery can be an effective treatment option.
NICE recommends referral for specialist assessment for bariatric surgery for adults with a BMI of 40 kg/m² or above, or a BMI between 35 and 39.9 kg/m² where there is a significant health condition that could improve with weight loss. There are lower BMI thresholds in certain circumstances, including for some people with recent-onset type 2 diabetes and for people from certain ethnic backgrounds because cardiometabolic risk can occur at lower BMI. [10]
Surgery is not a quick fix. It requires assessment by a multidisciplinary team and long-term follow-up, including nutritional monitoring. People considering surgery should understand both the potential benefits and the risks before making a decision. [10]
Which weight loss treatment is right for you?
There is no useful “best weight loss treatment” that applies to everybody.
Someone with a relatively small amount of weight to lose may benefit from structured nutritional and behavioural support. Someone with obesity and significant appetite difficulties may be considered for prescription medication. Another person may have medical or psychological factors that need addressing before weight loss treatment is started. For someone with severe obesity and associated health problems, bariatric surgery may form part of the discussion.
The important point is that treatment should be matched to the individual rather than selected because a particular medicine is currently popular.
If you are considering prescription treatment, a consultation with a qualified prescriber can establish whether medication is appropriate, which options are licensed and suitable for you, what you can reasonably expect from treatment, and what monitoring you will need.
A final word from me
Weight management can be frustrating, particularly if you have already tried several diets and found that the weight returned.
That does not mean you have failed. Weight regulation is biologically complex, and obesity is recognised as a chronic condition that may require ongoing treatment and support.
There are now more evidence-based treatment options available in the UK than there were a few years ago. The important thing is to choose an approach that is medically appropriate, properly prescribed and realistic for you to continue.
If medication is appropriate, it should sit alongside good nutrition, physical activity and behavioural support rather than replace them. And if medication is not appropriate, there are still structured ways to approach weight management without resorting to extreme diets.
The first step is a proper clinical assessment.
References
- National Institute for Health and Care Excellence (NICE). Overweight and obesity management (NG246). Updated January 2026.
- NICE. Overweight and obesity management: Identifying and assessing overweight, obesity and central adiposity. NG246.
- Medicines and Healthcare products Regulatory Agency (MHRA). GLP-1 medicines for weight loss and diabetes: what you need to know. Updated February 2026.
- NHS. Semaglutide: a medicine to manage type 2 diabetes or treat obesity. 2026.
- NICE. Tirzepatide for managing overweight and obesity (TA1026). 2024, with implementation guidance subsequently updated.
- Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine. 2022;387:1433–1444.
- NICE. Liraglutide for managing overweight and obesity (TA664). 2020.
- MHRA. GLP-1 receptor agonists and dual GLP-1/GIP receptor agonists: strengthened warnings on acute pancreatitis, including necrotising and fatal cases. January 2026.
- NHS England. Medicines for obesity and Interim commissioning guidance: NICE TA1026 tirzepatide. 2025–2026.
- NICE. Overweight and obesity management: Medicines and surgery. NG246.